Media
Press Releases
October 1, 2025
Lupin Launches Rivaroxaban for Oral Suspension in the United States
September 30, 2025
Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension
September 24, 2025
Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets
September 17, 2025
Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules
September 3, 2025
Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi’s Long-Acting Injectable Platform
August 20, 2025
Lupin Launches Bosentan Tablets for Oral Suspension in the United States with 180-Day Exclusivity
August 11, 2025
Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States
July 24, 2025
Lupin Receives US FDA Approvals for Liraglutide and Glucagon Injectable Products
July 16, 2025
Lupin Launches Loteprednol Etabonate Ophthalmic Suspension, 0.5% in the United States
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product